Effects of ramipril on platelet responsiveness to nitric oxide donors.A randomised,placebo controlled, double blind study in patients with high cardiovascular risk.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12606000003572

Acronym

Nil

Enrollment

120

Registered

2006-01-04

Start date

2003-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To see by what means or mechanism ACE inhibitors reduce the chance of heart attack or stoke

Interventions

Ramipril 10mg for 12 weeks

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

Have pmh of CAD,PVD or stroke or who have diabetes plus at least 1 CV risk(HOPE).

Exclusion criteria

ACE or ARB therapy or need to start same or contraindications to same.Less than 2 Ohms of ADP induced platelet aggregation at baseline.

Outcome results